Latest Stocks: Supernus Pharmaceuticals Inc (SUPN) Position Boosted by BNP Paribas Arbitrage SA

Latest Stocks: Supernus Pharmaceuticals Inc (SUPN) Position Boosted by BNP Paribas Arbitrage SA

BNP Paribas Arbitrage SA increased its position in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 1,265.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,760 shares of the specialty pharmaceutical company’s stock after buying an additional 128,598 shares during the period. BNP Paribas Arbitrage SA owned approximately 0.28% of Supernus Pharmaceuticals worth $4,343,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Suntrust Banks Inc. boosted its stake in Supernus Pharmaceuticals by 1.8% in the first quarter. Suntrust Banks Inc. now owns 19,913 shares of the specialty pharmaceutical company’s stock worth $622,000 after buying an additional 343 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Supernus Pharmaceuticals by 4.9% in the first quarter. Bank of New York Mellon Corp now owns 1,668,864 shares of the specialty pharmaceutical company’s stock valued at $52,236,000 after buying an additional 78,084 shares in the last quarter. American Century Companies Inc. boosted its stake in shares of Supernus Pharmaceuticals by 15.9% in the first quarter. American Century Companies Inc. now owns 285,664 shares of the specialty pharmaceutical company’s stock valued at $8,941,000 after buying an additional 39,124 shares in the last quarter. Algert Global LLC purchased a new stake in shares of Supernus Pharmaceuticals during the first quarter valued at $1,835,000. Finally, C WorldWide Group Holding A S boosted its stake in shares of Supernus Pharmaceuticals by 32.3% in the first quarter. C WorldWide Group Holding A S now owns 136,272 shares of the specialty pharmaceutical company’s stock valued at $4,265,000 after buying an additional 33,272 shares in the last quarter. 94.94% of the stock is owned by institutional investors and hedge funds.

Supernus Pharmaceuticals Inc (NASDAQ SUPN) opened at 39.05 on Tuesday. The stock has a 50 day moving average of $33.79 and a 200-day moving average of $28.15. Supernus Pharmaceuticals Inc has a 12 month low of $17.25 and a 12 month high of $41.20. The company has a market cap of $1.96 billion, a P/E ratio of 21.01 and a beta of 1.89.

Several analysts have recently commented on the stock. Piper Jaffray Companies raised shares of Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price target for the company from $30.00 to $44.00 in a research note on Thursday, June 1st. Jefferies Group LLC increased their price objective on shares of Supernus Pharmaceuticals from $35.00 to $45.00 and gave the company a “buy” rating in a report on Wednesday, May 31st. Cantor Fitzgerald increased their price objective on shares of Supernus Pharmaceuticals from $25.00 to $27.00 and gave the company an “overweight” rating in a report on Thursday, May 11th. Cowen and Company increased their price objective on shares of Supernus Pharmaceuticals from $31.00 to $34.00 and gave the company an “outperform” rating in a report on Thursday, May 11th. Finally, Stifel Nicolaus increased their target price on shares of Supernus Pharmaceuticals from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, April 3rd. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $33.43. In related news, CFO Gregory S. Patrick sold 54,000 shares of Supernus Pharmaceuticals stock in a transaction on Monday, April 24th. The shares were sold at an average price of $32.37, for a total value of $1,747,980.00. Following the sale, the chief financial officer now owns 54,221 shares in the company, valued at $1,755,133.77. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 11,806 shares of Supernus Pharmaceuticals stock in a transaction on Monday, April 24th. The shares were sold at an average price of $32.59, for a total transaction of $384,757.54. Following the completion of the sale, the vice president now owns 45,500 shares in the company, valued at approximately $1,482,845. The disclosure for this sale can be found here. In the last quarter, insiders sold 83,806 shares of company stock worth $2,813,038. 6.10% of the stock is currently owned by company insiders.

Receive News & Ratings for Supernus Pharmaceuticals Inc Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Supernus Pharmaceuticals Inc and related companies with MarketBeat.com’s FREE daily email newsletter.

Related posts

Leave a Comment